Defence Science and Technology Laboratory, UK
Melioidosis, vaccines, antimicrobials
Much of my early research career was on the development of a vaccine for bovine tuberculosis. This research included the development of diagnostic tools to discriminate vaccinated from infected animals (DIVA diagnostics), the subject of my PhD. Currently, I am the technical project lead on Government funded projects concerned with the development of therapeutics for other challenging facultative intracellular bacterial pathogens including Burkholderia, Francisella and Coxiella spp. Complementary to my continued vaccine interests, I am also currently leading projects concerned with assessing novel anti-microbials for the post-exposure treatment of these infections.
Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles. Whelan AO, Flick-Smith HC, Homan J, Shen ZT, Carpenter Z, Khoshkenar P, Abraham A, Walker NJ, Levitz SM, Ostroff GR, Oyston PCF. PLoS One. 2018 Oct 8;13(10):e0200213
An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia. Marshall LE, Nelson M, Davies CH, Whelan AO, Jenner DC, Moule MG, Denman C, Cuccui J, Atkins TP, Wren BW, Prior JL. J Immunol Res. 2018 Nov 29;2018:8087916
Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis. Scott AE, Burtnick MN, Stokes MG, Whelan AO, Williamson ED, Atkins TP, Prior JL, Brett PJ. Infect Immun. 2014 Aug;82(8):3206-13